Commentary to the article: ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59

scientific article published in June 2008

Commentary to the article: ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59 is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID18700309

P2093author name stringMarcin Dominiak
P433issue6
P304page(s)705-6; discussion 707
P577publication date2008-06-01
P1433published inKardiologia PolskaQ2775982
P1476titleCommentary to the article: ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59
P478volume66

Reverse relations

cites work (P2860)
Q26865691Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system
Q38223595Current therapeutic approaches to cardio-protection in hypertension
Q28535089Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan
Q37502956The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension
Q34094354The past, present and future of renin-angiotensin aldosterone system inhibition
Q53600013[Antihypertensive drug therapy : Where do we stand?].